The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3 : Randomized controlled phase II trial with 2.5 years of follow-up

Show full item record



Permalink

http://hdl.handle.net/10138/307221

Citation

Harper , D M , Nieminen , P , Donders , G , Einstein , M H , Garcia , F , Huh , W K , Stoler , M H , Glavini , K , Attley , G , Limacher , J-M , Bastien , B & Calleja , E 2019 , ' The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3 : Randomized controlled phase II trial with 2.5 years of follow-up ' , Gynecologic Oncology , vol. 153 , no. 3 , pp. 521-529 . https://doi.org/10.1016/j.ygyno.2019.03.250

Title: The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3 : Randomized controlled phase II trial with 2.5 years of follow-up
Author: Harper, Diane M.; Nieminen, Pekka; Donders, Gilbert; Einstein, Mark H.; Garcia, Francisco; Huh, Warner K.; Stoler, Mark H.; Glavini, Katerina; Attley, Gemma; Limacher, Jean-Marc; Bastien, Berangere; Calleja, Elizabeth
Contributor: University of Helsinki, HUS Gynecology and Obstetrics
Date: 2019-06
Language: eng
Number of pages: 9
Belongs to series: Gynecologic Oncology
ISSN: 0090-8258
URI: http://hdl.handle.net/10138/307221
Abstract: Background. While prophylactic human papillomavirus (HPV) vaccination exists, women are still developing cervical intraepithelial neoplasia (CIN) grade 2 or 3 for which an immunotherapeutic, non-surgical, approach may be effective. The primary aim was to assess the efficacy of tipapkinogen sovacivec (TS) vaccine in achieving histologic resolution of CIN2/3 associated with high risk (HR) HPV types. Methods. Women 18 years and older who had confirmed CIN2/3 were enrolled in a randomized, double blind, placebo-controlled phase II trial and assigned to drug in a 2:1 ratio (vaccine:placebo). The primary endpoint occurred at month 6 when the excisional therapy was performed; cytology and HR HPV typing were performed at months 3, 6 and every six months through month 30. The safety population included all patients who received at least one dose of study drug. Results. Of the 129 women randomized to vaccine and 63 to placebo, complete resolution was significantly higher in the vaccine group than placebo for CIN 2/3 regardless of the 13 HR HPV types assayed (24% vs. 10%, p <0.05); as well as for only CIN 3 also regardless of HR HPV type (21% vs. 0%, p <0.01). Irrespective of baseline HPV infection, viral DNA clearance was higher in the vaccine group compared to placebo (p <0.01). The vaccine was well tolerated with the most common adverse events being injection site reactions. Conclusions. The TS vaccine provides histologic clearance of CIN 2/3 irrespective of HR HPV type in one third of subjects and is generally safe through 30 months. (C) 2019 The Authors. Published by Elsevier Inc.
Subject: CIN 2/3
Immunotherapy
HPV
Cervical cancer
Therapeutic vaccine
Women
BIOPSIES
EXCISION
DISEASE
3122 Cancers
3123 Gynaecology and paediatrics
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
The_efficacy_an ... trolled_phase_II_trial.pdf 746.7Kb PDF View/Open
1_s2.0_S0090825819304846_main.pdf 766.8Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record